The groundbreaking rise of Sildenafil presented a significant opportunity for shareholders , but its patent has ended, creating a intricate landscape. Off-brand versions have entered the arena, cutting into sales and putting pressure on profit yields. While established pharmaceutical companies maintain a foothold in this area, the future remains cl